riluzole has been researched along with Reperfusion Injury in 6 studies
Riluzole: A glutamate antagonist (RECEPTORS, GLUTAMATE) used as an anticonvulsant (ANTICONVULSANTS) and to prolong the survival of patients with AMYOTROPHIC LATERAL SCLEROSIS.
Reperfusion Injury: Adverse functional, metabolic, or structural changes in tissues that result from the restoration of blood flow to the tissue (REPERFUSION) following ISCHEMIA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Riluzole treatment attenuated oxidative DNA damage in the spinal cord and postoperative decline after decompression surgery." | 6.80 | Riluzole blocks perioperative ischemia-reperfusion injury and enhances postdecompression outcomes in cervical spondylotic myelopathy. ( Arnold, P; Chung, YS; Fehlings, MG; Foltz, WD; Karadimas, SK; Laliberte, AM; Tetreault, L, 2015) |
| "Riluzole is a promising drug for the prevention of IRI in skeletal muscle, but further research is required." | 5.56 | Riluzole protects against skeletal muscle ischaemia-reperfusion injury in a porcine model. ( Chen, M; Deng, Y; Li, RW; Pham, HN; Smith, PN; Weiss, S, 2020) |
| "Riluzole has a neuroprotective effect in a rat model of spinal cord injury/reperfusion when administered up to 4h post-injury, a clinically relevant therapeutic time window." | 5.40 | Riluzole improves outcome following ischemia-reperfusion injury to the spinal cord by preventing delayed paraplegia. ( Fehlings, MG; Satkunendrarajah, K; Wu, Y, 2014) |
| " Riluzole, Lidocaine and Lamotrigine were given prior to renal ischemia only (IO) or IRI." | 4.12 | Pharmacological prevention of renal ischemia-reperfusion injury in a rat model. ( Deng, Y; Li, RW; Smith, PN; Weiss, S; Yang, YL, 2022) |
| "Riluzole treatment attenuated oxidative DNA damage in the spinal cord and postoperative decline after decompression surgery." | 2.80 | Riluzole blocks perioperative ischemia-reperfusion injury and enhances postdecompression outcomes in cervical spondylotic myelopathy. ( Arnold, P; Chung, YS; Fehlings, MG; Foltz, WD; Karadimas, SK; Laliberte, AM; Tetreault, L, 2015) |
| "Riluzole is a promising drug for the prevention of IRI in skeletal muscle, but further research is required." | 1.56 | Riluzole protects against skeletal muscle ischaemia-reperfusion injury in a porcine model. ( Chen, M; Deng, Y; Li, RW; Pham, HN; Smith, PN; Weiss, S, 2020) |
| "Riluzole has a neuroprotective effect in a rat model of spinal cord injury/reperfusion when administered up to 4h post-injury, a clinically relevant therapeutic time window." | 1.40 | Riluzole improves outcome following ischemia-reperfusion injury to the spinal cord by preventing delayed paraplegia. ( Fehlings, MG; Satkunendrarajah, K; Wu, Y, 2014) |
| "Riluzole was injected or topically applied to the eye before or after ischemia and twice daily during the reperfusion period." | 1.30 | Riluzole improves functional recovery after ischemia in the rat retina. ( Ettaiche, M; Fillacier, K; Heurteaux, C; Lazdunski, M; Widmann, C, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Anzini, M | 1 |
| Chelini, A | 1 |
| Mancini, A | 1 |
| Cappelli, A | 1 |
| Frosini, M | 1 |
| Ricci, L | 1 |
| Valoti, M | 1 |
| Magistretti, J | 1 |
| Castelli, L | 1 |
| Giordani, A | 1 |
| Makovec, F | 1 |
| Vomero, S | 1 |
| Deng, Y | 2 |
| Li, RW | 2 |
| Yang, YL | 1 |
| Weiss, S | 2 |
| Smith, PN | 2 |
| Pham, HN | 1 |
| Chen, M | 1 |
| Wu, Y | 1 |
| Satkunendrarajah, K | 1 |
| Fehlings, MG | 2 |
| Karadimas, SK | 1 |
| Laliberte, AM | 1 |
| Tetreault, L | 1 |
| Chung, YS | 1 |
| Arnold, P | 1 |
| Foltz, WD | 1 |
| Ettaiche, M | 1 |
| Fillacier, K | 1 |
| Widmann, C | 1 |
| Heurteaux, C | 1 |
| Lazdunski, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Regeneration in Cervical Degenerative Myelopathy - a Multi-centre, Double-blind, Randomised, Placebo Controlled Trial Assessing the Efficacy of Ibudilast as an Adjuvant Treatment to Decompressive Surgery for Degenerative Cervical Myelopathy[NCT04631471] | Phase 3 | 400 participants (Anticipated) | Interventional | 2021-12-22 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for riluzole and Reperfusion Injury
| Article | Year |
|---|---|
Riluzole blocks perioperative ischemia-reperfusion injury and enhances postdecompression outcomes in cervical spondylotic myelopathy.
Topics: Animals; Axons; Cervical Vertebrae; Decompression, Surgical; Disease Models, Animal; Humans; Magneti | 2015 |
5 other studies available for riluzole and Reperfusion Injury
| Article | Year |
|---|---|
Synthesis and biological evaluation of amidine, guanidine, and thiourea derivatives of 2-amino(6-trifluoromethoxy)benzothiazole as neuroprotective agents potentially useful in brain diseases.
Topics: Amidines; Animals; Antioxidants; Benzothiazoles; Brain Diseases; Calcium; Guanidines; Ion Transport; | 2010 |
Pharmacological prevention of renal ischemia-reperfusion injury in a rat model.
Topics: Animals; Glutathione; Humans; Ischemia; Kidney; Lamotrigine; Lidocaine; Rats; Reperfusion Injury; Ri | 2022 |
Riluzole protects against skeletal muscle ischaemia-reperfusion injury in a porcine model.
Topics: Animals; Apoptosis; Disease Models, Animal; Muscle, Skeletal; Random Allocation; Reperfusion Injury; | 2020 |
Riluzole improves outcome following ischemia-reperfusion injury to the spinal cord by preventing delayed paraplegia.
Topics: Animals; Female; Neuroprotective Agents; Paraplegia; Rats; Reperfusion Injury; Riluzole; Spinal Cord | 2014 |
Riluzole improves functional recovery after ischemia in the rat retina.
Topics: Administration, Topical; Animals; Apoptosis; Electroretinography; Glial Fibrillary Acidic Protein; I | 1999 |